What is ICCC's health score?

IMMUCELL CORP /DE/ (ICCC) has a TradeApes health score of 72 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ICCC's estimated fair value?

Based on our 5-year discounted cash flow model, IMMUCELL CORP /DE/'s estimated fair value is $0.41 per share, representing a -95.9% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is ICCC undervalued or overvalued?

Our model currently rates ICCC as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ICCC... Refresh in a moment for the full analysis.

IMMUCELL CORP /DE/ (ICCC)

Healthcare Overvalued low healthy

$9.87

Updated: 2026-06-05

TradeApes Score

Financial Strength

80 Strong

Operating Trend

68 Healthy

Relative Value

70 Healthy

Capital Allocation

65 Healthy

Risk

80 Strong

Est. Fair Value $0.41

DCF Upside -95.9%

Sector Rank #188 of 6694

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

1 free score card remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.